Douglas Laboratories Osteo-guard Plus Ipriflavone
Osteo-Guard® Plus Ipriflavone combines ipriflavone, a flavonoid, with calcium from microcrystalline calcium hydroxyapatite compound (MCHC) prepared from whole bone, and magnesium from amino acid chelate with excellent bioavailability. Osteo-Guard® Plus Ipriflavone also provides phosphorus (as microcrystalline hydroxyapatite), trace minerals, bone matrix proteins, amino acids, and glycosaminoglycans.
Each serving contains:
Vitamin D3 (as cholecalciferol) - 200 IU
Vitamin K1 (as phytonadione) - 100 mcg
Calcium (as microcrystalline hydroxyapatite) - 300 mg
Phosphorus (as microcrystalline hydroxyapatite) - 144 mg
Magnesium (as magnesium amino acid chelate) - 125 mg
Ipriflavone - 300 mg
Boron (as boron aspartate-citrate) - 0.25 mg
Other ingredients: Cellulose, calcium carbonate, dicalcium phosphate, croscarmellose sodium, vegetable stearate, silica, water, polyethylene glycol, magnesium silicate, (poly) ethenol, and polysorbate 80.
As a dietary supplement, adults take 2 tablets daily with food or as directed by your healthcare professional.
Bone is constantly turning over, a continuous process of formation and resorption. In normal aging, there is a gradual loss of bone. Ipriflavone helps promote bone density by inhibiting bone resorption. Numerous studies of postmenopausal women and individuals whose bones are showing signs of demineralization have investigated the benefits of ipriflavone on bone health. Laboratory and clinical studies have documented ipriflavone’s positive effect on bone density.
Osteoclasts and osteoblasts are two primary types of bone cells. Osteoblasts, the more exterior cells, are responsible for bone mineralization. Osteoclasts, found beneath the osteoblasts, are responsible for bone resorption. Experts agree that ipriflavone appears to directly inhibit osteoclast activity, thereby decreasing bone resorption. Scientists suspect ipriflavone may also stimulate osteoblast activity. Since osteoblasts are responsible for laying down new bone, an increase in osteoblast activity may result in increased bone mineralization. This suggests Ipriflavone may not only inhibit the breakdown of existing bone, but also encourage the formation of new bone.
In women, bone loss is generally accelerated following menopause. Ipriflavone, together with adequate calcium, vitamin D, vitamin K, and other key nutrients involved in bone health, offers non-estrogenic protection against excessive bone resorption. Unlike other well-known isoflavones, such as genistein found in soy foods, ipriflavone does not have estrogenic activity and can be safely used in conjunction with natural phytoestrogens or with hormone replacement therapy (HRT).